Ingmar Bruns
Keine laufenden Positionen mehr
Profil
Ingmar Bruns worked as the Chief Medical Officer at Trillium Therapeutics ULC from 2020 to 2021.
Prior to that, he held the position of Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns earned a doctorate degree from Universität zu Lübeck.
Ehemalige bekannte Positionen von Ingmar Bruns
| Unternehmen | Position | Ende |
|---|---|---|
| TRILLIUM THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 17.11.2021 |
| PIERIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Ingmar Bruns
| Universität zu Lübeck | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
